Investor Relations

News Releases

Date Title
03/27/17
Summary ToggleKemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum CORALVILLE, Iowa , March 27, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett , Ph.D., Senior Director, Scientific Affairs, will present at
03/16/17
Summary ToggleKemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting Poster Presentations Highlight Oral Equivalency and Intranasal Abuse Deterrence Technology CORALVILLE, Iowa , March 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,
03/09/17
Summary ToggleKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights : Reported Positive Data from Phase 1 Proof-of-Concept Clinical Trial of KP415 Received Clearance from FDA to Initiate Clinical Program for
02/28/17
Summary ToggleKemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  March 9th, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , Feb. 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
02/23/17
Summary ToggleKemPharm Announces Additional Patent Protection for Prodrug Portfolio US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family CORALVILLE, Iowa , Feb. 23, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
02/07/17
Summary ToggleKemPharm to Present at Upcoming Investor Conferences Management Presentations to Focus on Depth of Product Pipeline CORALVILLE, Iowa , Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and
01/09/17
Summary ToggleKemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain Statistically significant pharmacokinetic and pharmacodynamic differences of abuse potential were observed in the KP511.A01 Study CORALVILLE, Iowa , Jan. 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
01/04/17
Summary ToggleKemPharm to Present at Biotech Showcase 2017 CORALVILLE, Iowa , Jan. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle , Ph.D., will present